Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront
July 01, 2023 at 15:58 PM EDT
Cellular Biomedicine Group out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront, plus milestones. Also, Shanghai Laekna Therapeutics completed an IPO on the Hong Kong Exchange, raising $100 million.
